Skip to content

Study on the clinical efficacy and mechanism of Sijun Wupi Decoction in the treatment of refractory ascites due to liver cirrhosis based on the spleen governing transportation and chemistry

Study on the clinical efficacy and mechanism of Sijun Wupi Decoction in the treatment of refractory ascites due to liver cirrhosis based on the spleen governing transportation and chemistry

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200005701
Enrollment
Unknown
Registered
2022-03-14
Start date
2022-04-03
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory ascites due to liver cirrhosis

Interventions

therapy group:Sijun Wupi Decoction plus conventional western medicine treatment

Sponsors

Affiliated Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: (1) Meet the above-mentioned diagnostic criteria for refractory ascites due to liver cirrhosis; (2) Aged over 18 years old; (3) Sign the informed consent form.

Exclusion criteria

Exclusion criteria: (1) The patient is under 18 years old; (2) Patients with non-refractory ascites due to liver cirrhosis; (3) Patients with hepatocarcinoma, cardiogenic, tuberculosis and renal ascites; (4) Patients with compensatory cirrhosis and without ascites; (5) Patients with severe diseases of cardiovascular, kidney, hematopoietic system, nervous system, tumor disease and mental illness; (6) Patients with gastrointestinal bleeding; (7) Pregnant or lactating women.

Design outcomes

Primary

MeasureTime frame
Curative effect index;Diagnostic indicators;

Secondary

MeasureTime frame
Biological indicators;

Countries

China

Contacts

Public ContactHuang Ya juan
1370023019@qq.com13739055748

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026